Co-administration of 5-OP-RU (5-(2-oxopropylideneamino)-6D-ribitylaminouracil, microbial riboflavin-derived antigen) and CpG (Toll-like receptor 9 agonist) can suppress the HCC progression by activating MAIT cells to release IFN-γ and cytotoxic substances, together with the accumulation of CD8 + T cells and NK cells in vivo [124]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.